RELMADA THERAPEUTICS, INC. (RLMD) Corporate Subsidiaries
RELMADA THERAPEUTICS, INC. (RLMD) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: RLMD
CIK: 1553643
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: NV
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
CBIZ CPAs P.C.
Auditor SinceSince 12/31/2025 12:00:00 AM
Lead Engagement PartnerMohammed Asaduzzaman
Audit LocationHouston, Texas, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-09-11 | 2026-09-09 | OWNERSHIP DOCUMENT | 0001213900-26-098970 | View SEC Doc Filr Page |
| 4 | 2026-09-11 | 2026-09-09 | 4 Filing | 0001213900-26-098969 | View SEC Doc Filr Page |
| 8-K | 2026-09-08 | 2026-09-03 | CURRENT REPORT | 0001213900-26-097851 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0002050709-26-000025 | View SEC Doc Filr Page |
| 8-K | 2026-08-06 | 2026-08-06 | CURRENT REPORT | 0001213900-26-086190 | View SEC Doc Filr Page |
| 10-Q | 2026-08-06 | 2026-06-30 | QUARTERLY REPORT | 0001213900-26-086151 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-07-29 | — | SCHEDULE 13G Filing | 0002012383-26-002872 | View SEC Doc Filr Page |
| 8-K | 2026-07-28 | 2026-07-28 | CURRENT REPORT | 0001213900-26-082007 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-06-22 | — | SCHEDULE 13G Filing | 0001104659-26-076490 | View SEC Doc Filr Page |
| S-8 | 2026-06-18 | — | REGISTRATION STATEMENT | 0001213900-26-070097 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-06-09 | — | SCHEDULE 13G Filing | 0001738048-26-000066 | View SEC Doc Filr Page |
| 8-K | 2026-05-28 | 2026-05-27 | CURRENT REPORT | 0001213900-26-062184 | View SEC Doc Filr Page |
| S-3ASR | 2026-05-13 | — | REGISTRATION STATEMENT | 0001213900-26-055901 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-13 | — | SCHEDULE 13G/A Filing | 0000919574-26-002929 | View SEC Doc Filr Page |
| 8-K | 2026-05-12 | 2026-05-12 | CURRENT REPORT | 0001213900-26-055164 | View SEC Doc Filr Page |
| 10-Q | 2026-05-12 | 2026-03-31 | QUARTERLY REPORT | 0001213900-26-055059 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-05-04 | — | SCHEDULE 13G Filing | 0001831942-26-000017 | View SEC Doc Filr Page |
| DEFA14A | 2026-04-17 | — | DEFINITIVE ADDITIONAL MATERIALS | 0001213900-26-045194 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-17 | 2026-05-27 | PROXY STATEMENT | 0001213900-26-045192 | View SEC Doc Filr Page |
| EFFECT | 2026-04-09 | — | EFFECT Filing | 9999999995-26-001136 | View SEC Doc Filr Page |
| 424B3 | 2026-04-09 | — | PROSPECTUS | 0001213900-26-042007 | View SEC Doc Filr Page |
| CORRESP | 2026-04-07 | — | CORRESP Filing | 0001213900-26-040821 | View SEC Doc Filr Page |
| UPLOAD | 2026-04-07 | — | UPLOAD Filing | 0000000000-26-003470 | View SEC Doc Filr Page |
| PRE 14A | 2026-04-06 | 2026-04-06 | PROXY STATEMENT | 0001213900-26-040498 | View SEC Doc Filr Page |
| S-3 | 2026-04-03 | — | REGISTRATION STATEMENT | 0001213900-26-039967 | View SEC Doc Filr Page |